Literature DB >> 11168960

Chronic peritoneal dialysis in iron-deficient rats with solutions containing iron dextran.

D K Reddy1, H L Moore, J H Lee, R Saran, K D Nolph, R Khanna, Z J Twardowski.   

Abstract

BACKGROUND: We evaluated the effects of different concentrations of iron dextran administered through the intraperitoneal route, in iron-deficient rats, on hematocrit (Hct in percentage), serum iron (mg/dL), total iron binding capacity (TIBC in mg/dL), and the function and histology of the peritoneal membrane.
METHODS: Seventy-two male Sprague-Dawley rats weighing 85 to 110 g were divided into two groups and seven subgroups. Group I consisted of rats on iron-deficient chow, and group II consisted of rats on normal chow. Both groups contained dialysis control subgroups (N = 12: IA, IID), dialyzed with Dianeal solution, and tissue control subgroups (N = 6: IE, IIN), in which rats were not dialyzed and catheters were not implanted. Study group I contained the following study subgroups (N = 12): (B) rats dialyzed with Dianeal solution containing 2 mg/L of iron dextran and (C) rats dialyzed with Dianeal solution containing 1 mg/L of iron dextran. Group IID was dialyzed with Dianeal solution containing 2 mg/dL of iron dextran. Study duration was 12 weeks with peritoneal equilibration tests (PETs) performed at baseline, 6 weeks, and 12 weeks. Prior to baseline, rats were placed on iron-deficient chow or normal chow for three weeks. Dialysis was performed with three 25 mL volume exchanges per day. Hematocrit (Hct), serum iron (Fe), and total iron binding capacity (TIBC) were determined for each study interval. After the final PET, the animals were sacrificed, and the peritoneal membrane was evaluated by gross inspection and light microscopy.
RESULTS: Rats on an iron-deficient diet developed severe iron-deficiency anemia after three weeks of the diet (Hct 27; Fe 21 to 23; TIBC 799 to 806). After 12 weeks, the rats remained anemic in groups A (Hct 34 +/- 0.9; Fe 16 +/- 2; TIBC 998 +/- 27) and IE (Hct 38 +/- 2.7), whereas the rats corrected anemia in group B (Hct 45.8 +/- 1.8; Fe 115 +/- 15; TIBC 546 +/- 77). The results were not significantly different from those of group IID (Hct 47.1 +/- 1.6; Fe 94 +/- 19; TIBC 516 +/- 46). In group C, Hct (44.8 +/- 2.1) and Fe (94 +/- 19) did not differ significantly from group IID, but TIBC (734 +/- 76) remained significantly higher than that in the group IID. Peritoneal iron deposits were not detected. The morphometric analysis of the submesothelial space did not reveal any difference in thickness between dialysis groups. PETs were not significantly different among groups.
CONCLUSIONS: Intraperitoneal iron dextran supplementation in concentrations of 2 mg/L of dialysis solution is nontoxic to the peritoneum and effective in correcting iron deficiency in rats maintained on an iron-deficient diet. Iron dextran in concentration of 1 mg/L of dialysis solution may be sufficient for correcting a lesser degree of iron deficiency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168960     DOI: 10.1046/j.1523-1755.2001.059002764.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  3 in total

1.  In vivo assessment of experimental neonatal excitotoxic brain lesion with USPIO-enhanced MR imaging.

Authors:  Marianne Alison; Robin Azoulay; François Chalard; Pierre Gressens; Guy Sebag
Journal:  Eur Radiol       Date:  2010-09       Impact factor: 5.315

2.  Histological study of the biodynamics of iron oxide nanoparticles with different diameters.

Authors:  Keiko Tsuchiya; Norihisa Nitta; Akinaga Sonoda; Ayumi Nitta-Seko; Shinichi Ohta; Hideji Otani; Masashi Takahashi; Kiyoshi Murata; Katsutoshi Murase; Satoshi Nohara; Kenichi Mukaisho
Journal:  Int J Nanomedicine       Date:  2011-08-02

Review 3.  The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee.

Authors:  Cornelis H Schröder
Journal:  Pediatr Nephrol       Date:  2003-05-15       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.